论文部分内容阅读
目的:探讨血清前列腺特异性抗原(PSA)与前列腺癌(PCa)临床分期、病理分级的相关性。方法:对自2004年7月~2009年12月南京市13692例50岁以上的男性在健康体检时行血清PSA检测。以PSA≥4.0ng/ml定为前列腺癌可疑病例。建议行前列腺穿刺活检以确诊。共筛查出PCa患者140例,比较不同PSA值PCa患者的Gleason评分及临床分期。结果:随着PSA值的升高,前列腺癌筛查阳性率亦随之升高,低分化前列腺癌患者血清PSA含量明显高于高分化前列腺癌和中分化前列腺癌患者(P<0.05),晚期前列腺癌患者血清PSA含量明显高于早期PCa患者(P<0.01)。血清PSA含量≥20ng/ml的前列腺癌人群中低分化前列腺癌及晚期前列腺癌的比例高于血清PSA含量<20ng/ml的前列腺癌人群(P<0.01)。结论:血清PSA可以为前列腺癌患者的诊断、治疗及预后判断提供重要依据。
Objective: To investigate the correlation between serum prostate specific antigen (PSA) and clinical stage and pathological grade of prostate cancer (PCa). Methods: From July 2004 to December 2009, 13 692 men over the age of 50 in Nanjing were tested for serum PSA during physical examination. PSA≥4.0ng / ml as suspicious cases of prostate cancer. Proposed prostate biopsy to confirm. A total of 140 cases of PCa were screened, and the Gleason score and clinical stage of PCa patients with different PSA values were compared. Results: With the increase of PSA value, the positive rate of prostate cancer screening also increased. The serum PSA level in patients with poorly differentiated prostate cancer was significantly higher than that in well-differentiated and moderately-differentiated prostate cancer patients (P <0.05) The serum PSA level of patients with prostate cancer was significantly higher than that of patients with early PCa (P <0.01). The proportion of poorly differentiated prostate cancer and advanced prostate cancer among those with PSA levels> 20 ng / ml was higher than those with PSA levels <20 ng / ml (P <0.01). Conclusion: Serum PSA can provide an important basis for the diagnosis, treatment and prognosis of patients with prostate cancer.